PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2688030-10 1989 TNF cytotoxic effects appeared to be amplified by pretreatment of cells with chemotherapeutic agents such as Actinomycin D, Adriamycin, and Cytoxan as well as to have synergistic effects with gamma interferon, alpha interferon, and IL-2. Doxorubicin 124-134 tumor necrosis factor Homo sapiens 0-3 3291772-11 1988 A synergistic increase in the cytotoxic effects of rH-TNF and anti-cancer drugs was demonstrated in vitro The cytotoxicity of rH-TNF against L-M cells in combination with MMC, ADM, Ara-C, ACD, DM, CDDP, VCR and 5-FU was 4 to 347 times as high as that of rH-TNF alone. Doxorubicin 176-179 tumor necrosis factor Homo sapiens 54-57 2838845-7 1988 Simultaneous comparison of tumor responsiveness to doxorubicin and TNF revealed a positive correlation in ID90 values; these results may have important implications for the clinical use of TNF in cancer patients heavily pretreated with doxorubicin. Doxorubicin 51-62 tumor necrosis factor Homo sapiens 189-192 2838845-7 1988 Simultaneous comparison of tumor responsiveness to doxorubicin and TNF revealed a positive correlation in ID90 values; these results may have important implications for the clinical use of TNF in cancer patients heavily pretreated with doxorubicin. Doxorubicin 236-247 tumor necrosis factor Homo sapiens 67-70 2838845-7 1988 Simultaneous comparison of tumor responsiveness to doxorubicin and TNF revealed a positive correlation in ID90 values; these results may have important implications for the clinical use of TNF in cancer patients heavily pretreated with doxorubicin. Doxorubicin 236-247 tumor necrosis factor Homo sapiens 189-192 3291772-11 1988 A synergistic increase in the cytotoxic effects of rH-TNF and anti-cancer drugs was demonstrated in vitro The cytotoxicity of rH-TNF against L-M cells in combination with MMC, ADM, Ara-C, ACD, DM, CDDP, VCR and 5-FU was 4 to 347 times as high as that of rH-TNF alone. Doxorubicin 176-179 tumor necrosis factor Homo sapiens 129-132 3291772-11 1988 A synergistic increase in the cytotoxic effects of rH-TNF and anti-cancer drugs was demonstrated in vitro The cytotoxicity of rH-TNF against L-M cells in combination with MMC, ADM, Ara-C, ACD, DM, CDDP, VCR and 5-FU was 4 to 347 times as high as that of rH-TNF alone. Doxorubicin 176-179 tumor necrosis factor Homo sapiens 129-132 32770328-5 2021 Correspondingly, the analysis of histopathological morphology showed that the morphology and density of tumor tissue in hydrogel/DOX treatment group changed obviously by using hematoxylin and eosin (H&E) staining assay, meanwhile cleaved caspase-3 (caspase-3) and tumor necrosis factor (TNF-alpha) were expressed at high levels tumors tissue in hydrogel/DOX treatment group by using immunohistochemical (IHC) staining. Doxorubicin 129-132 tumor necrosis factor Homo sapiens 264-285 32770328-5 2021 Correspondingly, the analysis of histopathological morphology showed that the morphology and density of tumor tissue in hydrogel/DOX treatment group changed obviously by using hematoxylin and eosin (H&E) staining assay, meanwhile cleaved caspase-3 (caspase-3) and tumor necrosis factor (TNF-alpha) were expressed at high levels tumors tissue in hydrogel/DOX treatment group by using immunohistochemical (IHC) staining. Doxorubicin 129-132 tumor necrosis factor Homo sapiens 287-296 33480330-5 2021 Results: Our results showed that DOX treatment led to increased hsCRP (4.80 +- 1.23 mg/dL, p = 0.0005), triglycerides (187.6 +- 25.06, p = 0.0231), TNF-alpha (42.31 +- 17.96 pg/mL, p = 0.01) and Fe levels (138.8 +- 18.6 mug/dL, p = 0.0193). Doxorubicin 33-36 tumor necrosis factor Homo sapiens 148-157 33834754-3 2021 To activate NK cell-based immuno-chemotherapy and enhance the tumor retention, we proposed a pH-responsive self-aggregated nanoparticle for the codelivery of chemotherapeutic doxorubicin (DOX) and the transforming growth factor-beta (TGF-beta)/Smad3 signaling pathway inhibitor SIS3. Doxorubicin 175-186 tumor necrosis factor Homo sapiens 201-232 33834754-3 2021 To activate NK cell-based immuno-chemotherapy and enhance the tumor retention, we proposed a pH-responsive self-aggregated nanoparticle for the codelivery of chemotherapeutic doxorubicin (DOX) and the transforming growth factor-beta (TGF-beta)/Smad3 signaling pathway inhibitor SIS3. Doxorubicin 188-191 tumor necrosis factor Homo sapiens 201-232 32418059-6 2020 Here, we report that doxorubicin synergizes with Smac mimetic to trigger TNF-mediated apoptosis, which is mechanistically distinct from doxorubicin-induced cell death. Doxorubicin 21-32 tumor necrosis factor Homo sapiens 73-76 31630586-8 2020 Significant increased activation of TNF-alpha, Caspase-3 activity and myocardial infarct size in DOX-treated group. Doxorubicin 97-100 tumor necrosis factor Homo sapiens 36-45 32418059-11 2020 These in vitro findings demonstrate that combination of Smac mimetic and doxorubicin synergistically triggers apoptosis through the TNF/CYLD/RIPK1/FADD/caspase-8 signaling pathway. Doxorubicin 73-84 tumor necrosis factor Homo sapiens 132-135 32225068-0 2020 Upregulation of CASP9 through NF-kappaB and Its Target MiR-1276 Contributed to TNFalpha-promoted Apoptosis of Cancer Cells Induced by Doxorubicin. Doxorubicin 134-145 tumor necrosis factor Homo sapiens 79-87 32225068-7 2020 This opinion was supported by the following evidence: TNFalpha promoted the apoptosis of HeLa and HepG2 cells induced by doxorubicin (DOX). Doxorubicin 121-132 tumor necrosis factor Homo sapiens 54-62 32225068-7 2020 This opinion was supported by the following evidence: TNFalpha promoted the apoptosis of HeLa and HepG2 cells induced by doxorubicin (DOX). Doxorubicin 134-137 tumor necrosis factor Homo sapiens 54-62 32225068-8 2020 CASP9 was significantly upregulated and activated by TNFalpha in the DOX-induced cells. Doxorubicin 69-72 tumor necrosis factor Homo sapiens 53-61 32225068-9 2020 Moreover, a known inhibitor of CASP9 activation significantly repressed the TNFalpha promotion of apoptosis induced by DOX. Doxorubicin 119-122 tumor necrosis factor Homo sapiens 76-84 32225068-12 2020 The results also shed new light on the molecular mechanism underlying TNFalpha-promotion of cancer cells apoptosis induced by some anticancer drugs such as DOX. Doxorubicin 156-159 tumor necrosis factor Homo sapiens 70-78 30880468-5 2019 The combination of DOX and KIR may promote therapeutic efficacy, at which the anti-apoptotic effect of the tumour cells was inhibited (by downregulating Bcl-2 and upregulating Bax) and the tumour progression-related inflammatory factors, such as tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) were downregulated. Doxorubicin 19-22 tumor necrosis factor Homo sapiens 276-285 30996116-6 2019 DOX influenced inflammatory responses by inducing a significant increase in the expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and cyclooxigenase-2 (COX-2), of inflammatory interleukins (IL), such as interleukin-6 (IL-6) and interleukin-8 (IL-8), and the inflammatory proteins mediators metalloproteinase-2 and metalloproteinase-9 (MMP2 and MMP9). Doxorubicin 0-3 tumor necrosis factor Homo sapiens 130-157 31645610-3 2019 Based on the results of transcriptomics analysis, we found 71 differentially expressed genes that are specific for the combination treatment with Doxorubicin + Estradiol + TNFalpha in comparison with single or double treatments. Doxorubicin 146-157 tumor necrosis factor Homo sapiens 172-180 31645610-7 2019 These results provide a model of coordinated interaction of TFs to explain the Doxorubicin, E2 and TNFalpha induced repression mechanisms. Doxorubicin 79-90 tumor necrosis factor Homo sapiens 99-107 31131472-0 2019 Smad4 gene silencing enhances the chemosensitivity of human lymphoma cells to adriamycin via inhibition of the activation of transforming growth factor beta signaling pathway. Doxorubicin 78-88 tumor necrosis factor Homo sapiens 125-156 31131472-2 2019 Our research was taken to identify the effects of lentiviral-mediated Smad4 gene silencing on chemosensitivity of human lymphoma cells to adriamycin (ADM) via transforming growth factor beta (TGFbeta) signaling pathway. Doxorubicin 138-148 tumor necrosis factor Homo sapiens 159-190 31131472-2 2019 Our research was taken to identify the effects of lentiviral-mediated Smad4 gene silencing on chemosensitivity of human lymphoma cells to adriamycin (ADM) via transforming growth factor beta (TGFbeta) signaling pathway. Doxorubicin 150-153 tumor necrosis factor Homo sapiens 159-190 31086347-7 2019 This was further supported by enrichment among upregulated genes related to inflammation, JAK-STAT and TNF-alpha signaling after doxorubicin. Doxorubicin 129-140 tumor necrosis factor Homo sapiens 103-112 30996116-6 2019 DOX influenced inflammatory responses by inducing a significant increase in the expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and cyclooxigenase-2 (COX-2), of inflammatory interleukins (IL), such as interleukin-6 (IL-6) and interleukin-8 (IL-8), and the inflammatory proteins mediators metalloproteinase-2 and metalloproteinase-9 (MMP2 and MMP9). Doxorubicin 0-3 tumor necrosis factor Homo sapiens 159-168 28096970-2 2016 Previous studies have demonstrated that MCF-7 cell line and its doxorubicin resistant variant MCF-7/Adr are resistant against the cytotoxic effects of TNF-alpha. Doxorubicin 64-75 tumor necrosis factor Homo sapiens 151-160 30503721-4 2019 KEY FINDINGS: Data showed that doxorubicin + geopropolis diminished IL-6 secretion, stimulated TNF-alpha and IL-10 production, TLR-4 and CD80 expression, NF-kappaB and autophagy pathway, as well as the bactericidal activity. Doxorubicin 31-42 tumor necrosis factor Homo sapiens 95-104 28025135-4 2017 Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-alpha. Doxorubicin 13-24 tumor necrosis factor Homo sapiens 103-112 26415122-6 2017 Doxorubicin, at low nontoxic doses, potentiated TNFalpha-induced activation of NF-kappaB and HIF, without effects in stand-alone treatment. Doxorubicin 0-11 tumor necrosis factor Homo sapiens 48-56 26225838-0 2015 Superoxide induces protein oxidation in plasma and TNF-alpha elevation in macrophage culture: Insights into mechanisms of neurotoxicity following doxorubicin chemotherapy. Doxorubicin 146-157 tumor necrosis factor Homo sapiens 51-60 26225838-4 2015 Our group previously demonstrated that Dox, which does not cross the BBB, induced oxidative damage to plasma proteins leading to TNF-alpha elevation in the periphery and, subsequently, in brain following cancer chemotherapy. Doxorubicin 39-42 tumor necrosis factor Homo sapiens 129-138 26225838-6 2015 The current study tested the notion that O2(-) is involved and likely responsible for Dox-induced plasma protein oxidation and TNF-alpha release. Doxorubicin 87-90 tumor necrosis factor Homo sapiens 128-137 26225838-10 2015 These findings, together with our prior results, provide strong evidence that O2(-) and its resulting reactive species are critically involved in Dox-induced plasma protein oxidation and TNF-alpha release. Doxorubicin 147-150 tumor necrosis factor Homo sapiens 188-197 25401416-7 2014 Transcriptome data were confirmed for 12 of 15 selected genes and seven (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) were synergistically up-regulated after Doxo+TNFalpha and dependent both on p53 and NFkappaB. Doxorubicin 159-163 tumor necrosis factor Homo sapiens 164-172 25909710-9 2015 CONCLUSIONS: The extracellular anti-oxidant mesna, when co-administered during a single cycle of doxorubicin, reduced levels of TNF-alpha and its receptors after that cycle of therapy, demonstrating for the first time a clinical interaction between mesna and doxorubicin, drugs often coincidentally co-administered in multi-agent regimens. Doxorubicin 259-270 tumor necrosis factor Homo sapiens 128-137 25401416-3 2014 Transcriptome analyses upon single or combined treatments with doxorubicin (Doxo, 1.5muM) and the NFkappaB inducer TNF-alpha (TNFalpha, 5ng/ml) revealed 432 up-regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFalpha treatment. Doxorubicin 63-74 tumor necrosis factor Homo sapiens 241-249 24336081-0 2013 TNF/TNF-R1 pathway is involved in doxorubicin-induced acute sterile inflammation. Doxorubicin 34-45 tumor necrosis factor Homo sapiens 0-3 25401416-3 2014 Transcriptome analyses upon single or combined treatments with doxorubicin (Doxo, 1.5muM) and the NFkappaB inducer TNF-alpha (TNFalpha, 5ng/ml) revealed 432 up-regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFalpha treatment. Doxorubicin 236-240 tumor necrosis factor Homo sapiens 115-124 25401416-3 2014 Transcriptome analyses upon single or combined treatments with doxorubicin (Doxo, 1.5muM) and the NFkappaB inducer TNF-alpha (TNFalpha, 5ng/ml) revealed 432 up-regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFalpha treatment. Doxorubicin 236-240 tumor necrosis factor Homo sapiens 126-134 24466321-0 2014 Tumor vasculature-targeted recombinant mutated human TNF-alpha enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models. Doxorubicin 98-109 tumor necrosis factor Homo sapiens 53-62 23887603-6 2013 The antibody-based pharmacodelivery of TNF by the fusion protein "F8-TNF" to oncofetal fibronectin in sarcoma-bearing mice leads to complete and long-lasting tumour eradications when administered in combination with doxorubicin, the first-line drug for the treatment of sarcomas in humans. Doxorubicin 216-227 tumor necrosis factor Homo sapiens 69-72 23866034-7 2013 Our results show doxorubicin-stimulated production of TNFalpha, whereas enzastaurin-stimulated TNFR-1 expression on plasma membrane. Doxorubicin 17-28 tumor necrosis factor Homo sapiens 54-62 23866034-9 2013 Taken together, our findings suggest that enzastaurin increases doxorubicin-induced apoptosis of melanoma by a mechanism involving, at least in part, activation of the TNF-alpha signal. Doxorubicin 64-75 tumor necrosis factor Homo sapiens 168-177 22644293-1 2012 BACKGROUND: The NGR-hTNF (asparagine-glycine-arginine-human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood vessels. Doxorubicin 164-175 tumor necrosis factor Homo sapiens 20-24 22907335-6 2013 We demonstrated that doxorubicin and vinblastine significantly impair the release of tumor necrosis factor-alpha, interleukin (IL)-6 and IL-12 by slanDCs. Doxorubicin 21-32 tumor necrosis factor Homo sapiens 85-112 21959683-4 2012 Our findings included an immediate plasmatic reduction in IL-1, IL-10, and TNF-alpha levels in doxorubicin-treated patients, as well as high levels of IL-10 in paclitaxel patients. Doxorubicin 95-106 tumor necrosis factor Homo sapiens 75-84 22429871-4 2012 Administration of Dox (20 mg/kg body weight, once) significantly enhanced levels of blood urea nitrogen (BUN), creatinine, uric acid, TNF-alpha, urinary gamma-glutamyl transpeptidase (gamma-GT) activity, total urinary protein and urinary glucose level. Doxorubicin 18-21 tumor necrosis factor Homo sapiens 134-143 23028726-5 2012 Doxorubicin treatment showed the following dose-dependent effects: increase in the secretion of tumor necrosis factor alpha; decrease in the expression of phosphorylated protein kinase A and Bcl-2; and increase in the expression of phosphorylated signal transducer and activator of transcription 3, phosphorylated extracellular signal-regulated kinase (ERK), and ATF3. Doxorubicin 0-11 tumor necrosis factor Homo sapiens 96-123 21387297-4 2012 Here, we report that JG3 inhibits NF-kappaB activation by specifically antagonizing the doxorubicin-triggered Ataxia-telangiectasia-mutated kinase (ATM) and the sequential MEK/ERK/p90Rsk/IKK signaling pathway but does not interfere with TNF-alpha-mediated NF-kappaB activation. Doxorubicin 88-99 tumor necrosis factor Homo sapiens 237-246 21421044-6 2011 We observed increased plasma protein carbonylation and elevation of TNF-alpha 6 h after DOX administration in the context of multiagent chemotherapy regimens. Doxorubicin 88-91 tumor necrosis factor Homo sapiens 68-77 16465414-1 2006 We previously demonstrated the doxorubicin-induced expression of urokinase-type plasminogen activator (uPA), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha in human RC-K8 lymphoma cells and NCI-H69 small cell lung carcinoma cells in which reactive oxygen species might be involved. Doxorubicin 31-42 tumor necrosis factor Homo sapiens 167-205 19212691-2 2009 We show here the inhibitory effect of tumor necrosis factor alpha (TNFalpha), a proinflammatory cytokine, on hemoglobinization and erythroid transcription factor GATA-1 expression in erythroleukemia (HEL) as well as in chronic myelogenous leukemia (K562) cells, which were induced to differentiate towards the erythroid lineage after aclacinomycin (Acla), doxorubicin (Dox) or hemin (HM) treatment. Doxorubicin 356-367 tumor necrosis factor Homo sapiens 38-65 19212691-2 2009 We show here the inhibitory effect of tumor necrosis factor alpha (TNFalpha), a proinflammatory cytokine, on hemoglobinization and erythroid transcription factor GATA-1 expression in erythroleukemia (HEL) as well as in chronic myelogenous leukemia (K562) cells, which were induced to differentiate towards the erythroid lineage after aclacinomycin (Acla), doxorubicin (Dox) or hemin (HM) treatment. Doxorubicin 356-367 tumor necrosis factor Homo sapiens 67-75 19212691-2 2009 We show here the inhibitory effect of tumor necrosis factor alpha (TNFalpha), a proinflammatory cytokine, on hemoglobinization and erythroid transcription factor GATA-1 expression in erythroleukemia (HEL) as well as in chronic myelogenous leukemia (K562) cells, which were induced to differentiate towards the erythroid lineage after aclacinomycin (Acla), doxorubicin (Dox) or hemin (HM) treatment. Doxorubicin 369-372 tumor necrosis factor Homo sapiens 38-65 19212691-2 2009 We show here the inhibitory effect of tumor necrosis factor alpha (TNFalpha), a proinflammatory cytokine, on hemoglobinization and erythroid transcription factor GATA-1 expression in erythroleukemia (HEL) as well as in chronic myelogenous leukemia (K562) cells, which were induced to differentiate towards the erythroid lineage after aclacinomycin (Acla), doxorubicin (Dox) or hemin (HM) treatment. Doxorubicin 369-372 tumor necrosis factor Homo sapiens 67-75 19967054-3 2008 Here, we report that the receptor interacting protein (RIP), a key adaptor protein of TNF signaling, was required to activate JNK in the cells treated with certain DNA damaging agents such as adriamycin (Adr) and 1-beta-D-arabinofuranosylcytosine (Ara-C) that cause slow and sustained activation, but it was not required when treated with N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and short wavelength UV, which causes quick and transient activation. Doxorubicin 192-202 tumor necrosis factor Homo sapiens 86-89 16388856-13 2006 Pretreatment with TNFalpha (10 ng/mL) increased apoptosis in PTX- or ADM-treated U937 cells. Doxorubicin 69-72 tumor necrosis factor Homo sapiens 18-26 21097524-0 2011 TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness. Doxorubicin 29-40 tumor necrosis factor Homo sapiens 0-3 21097524-2 2011 Tumor necrosis factor-alpha (TNF), a proinflammatory cytokine that depresses diaphragm force, is elevated following doxorubicin chemotherapy. Doxorubicin 116-127 tumor necrosis factor Homo sapiens 0-27 21097524-2 2011 Tumor necrosis factor-alpha (TNF), a proinflammatory cytokine that depresses diaphragm force, is elevated following doxorubicin chemotherapy. Doxorubicin 116-127 tumor necrosis factor Homo sapiens 29-32 21097524-4 2011 These findings lead us to hypothesize that TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm muscle weakness. Doxorubicin 72-83 tumor necrosis factor Homo sapiens 43-46 21097524-8 2011 Etanercept, a soluble TNF receptor, and TNFR1 deficiency protected against the depression in diaphragm-specific force caused by doxorubicin. Doxorubicin 128-139 tumor necrosis factor Homo sapiens 22-25 21097524-10 2011 These results suggest that doxorubicin increases diaphragm sensitivity to TNF by upregulating TNFR1, thereby causing respiratory muscle weakness. Doxorubicin 27-38 tumor necrosis factor Homo sapiens 74-77 18400355-0 2008 Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms. Doxorubicin 17-28 tumor necrosis factor Homo sapiens 60-69 18505924-5 2008 Tumor necrosis factor-alpha up-regulates nSMase3 expression within 2 h that lasts beyond 24 h and declines to control levels by 36 h. Adriamycin up-regulation of nSMase3 is transient, occurs within 30 min, and declines to control levels by 120 min. Doxorubicin 134-144 tumor necrosis factor Homo sapiens 0-27 17013758-4 2006 In contrast to the well established role of caspase-3 as an effector caspase, the focus of this study is to delineate caspase-3 induced feedback activation of the apical caspases-2, -8, -9 and -10A in doxorubicin and TNF-alpha induced apoptosis. Doxorubicin 201-212 tumor necrosis factor Homo sapiens 217-226 17047073-7 2006 Importantly, down-regulation of TRAIL by small interfering RNA silencing decreased TNFalpha-mediated Adriamycin-induced caspase activation and apoptosis, and thus enhanced breast cancer cell resistance to Adriamycin. Doxorubicin 101-111 tumor necrosis factor Homo sapiens 83-91 17047073-7 2006 Importantly, down-regulation of TRAIL by small interfering RNA silencing decreased TNFalpha-mediated Adriamycin-induced caspase activation and apoptosis, and thus enhanced breast cancer cell resistance to Adriamycin. Doxorubicin 205-215 tumor necrosis factor Homo sapiens 83-91 16483679-0 2006 A combined treatment TNF-alpha/doxorubicin alleviates the resistance of MCF-7/Adr cells to cytotoxic treatment. Doxorubicin 31-42 tumor necrosis factor Homo sapiens 21-30 16483679-4 2006 Treatment of cells with TNF-alpha following doxorubicin (DOX) resulted in a decrease of the activated Rel A/p65 in nuclei. Doxorubicin 44-55 tumor necrosis factor Homo sapiens 24-33 16483679-4 2006 Treatment of cells with TNF-alpha following doxorubicin (DOX) resulted in a decrease of the activated Rel A/p65 in nuclei. Doxorubicin 57-60 tumor necrosis factor Homo sapiens 24-33 16483679-6 2006 The combined treatment of TNF-alpha/DOX also resulted in a significant decrease of mRNA levels of anti-apoptotic genes, such as the cellular inhibitor of apoptosis-1 (c-IAP1), and the long isoform of B cell leukemia/lymphoma x gene (Bcl-xL), leading to efficient induction of caspase-8 cleavage and cell death. Doxorubicin 36-39 tumor necrosis factor Homo sapiens 26-35 16483679-7 2006 In previous work, we demonstrated that TNF-alpha promotes DOX-induced cell death and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. Doxorubicin 58-61 tumor necrosis factor Homo sapiens 39-48 16871999-6 2006 Treatment with adriamycin for three cycles produced a significant decrease in TNF-alpha, sP-selectin and GST. Doxorubicin 15-25 tumor necrosis factor Homo sapiens 78-87 16437946-2 2005 Two different studies were performed: the first was carried out to analyze the doxorubicin-TNFalpha-hyperthermia association (three different trials) in terms of toxicity and efficacy of the treatment (tumor response, locoregional control, disease free and overall survival). Doxorubicin 79-90 tumor necrosis factor Homo sapiens 91-99 15823547-0 2005 TNF-alpha promotes Doxorubicin-induced cell apoptosis and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. Doxorubicin 19-30 tumor necrosis factor Homo sapiens 0-9 15823547-4 2005 Treatment of cells with TNF-alpha resulted in a decrease of p21 (waf1/cip1/sdi1) expression following second dose of DOX. Doxorubicin 117-120 tumor necrosis factor Homo sapiens 24-33 15823547-6 2005 Thus, we propose that TNF-alpha enhances the anti-cancer effect of DOX through suppressing the anti-apoptotic activity of p21, and that a combined treatment TNF-alpha/Dox is an effective chemotherapeutic strategy for p53-deficient cancers. Doxorubicin 67-70 tumor necrosis factor Homo sapiens 22-31 15823547-6 2005 Thus, we propose that TNF-alpha enhances the anti-cancer effect of DOX through suppressing the anti-apoptotic activity of p21, and that a combined treatment TNF-alpha/Dox is an effective chemotherapeutic strategy for p53-deficient cancers. Doxorubicin 67-70 tumor necrosis factor Homo sapiens 157-166 16437946-3 2005 The results showed that the trimodality association (doxorubicin TNFalpha and hyperthermia) is the best regimen able to obtain a 77% of objective response and 77% of limb sparing in patients candidate to amputation but may result in high local toxicity if high temperatures (>41.5 degrees C) were maintained during perfusion. Doxorubicin 53-64 tumor necrosis factor Homo sapiens 65-73 15359114-9 2004 Finally, we confirmed that NK cells produce TNF alpha, and that doxorubicin-sensitive Raji cells become doxorubicin-resistant after TNF alpha treatment. Doxorubicin 64-75 tumor necrosis factor Homo sapiens 132-141 15810080-11 2005 The expression of TNF-alpha was significantly higher in NS group than that in DOX group (average 1.40+/-0.17 vs 0.62+/-0.22, P<0.01) at serial time points after SFC. Doxorubicin 78-81 tumor necrosis factor Homo sapiens 18-27 15359114-9 2004 Finally, we confirmed that NK cells produce TNF alpha, and that doxorubicin-sensitive Raji cells become doxorubicin-resistant after TNF alpha treatment. Doxorubicin 104-115 tumor necrosis factor Homo sapiens 132-141 15359114-10 2004 Taken together, these results suggest that B lymphoma cell resistance to doxorubicin-mediated cell death is induced by coculture with NK cells, because of TNF alpha secretion. Doxorubicin 73-84 tumor necrosis factor Homo sapiens 155-164 15367711-2 2004 We report here that Ad.Egr-TNF.11D is activated by the clinically important anticancer agents cisplatin, cyclophosphamide, doxorubicin, 5-fluorouracil, gemcitabine, and paclitaxel. Doxorubicin 123-134 tumor necrosis factor Homo sapiens 27-30 15053878-2 2004 Here, we demonstrate that NF-kappa B induced by cytotoxic stimuli, such as ultraviolet light (UV-C) and the chemotherapeutic drugs daunorubicin/doxorubicin, is functionally distinct to that seen with the inflammatory cytokine TNF and is an active repressor of antiapoptotic gene expression. Doxorubicin 144-155 tumor necrosis factor Homo sapiens 226-229 15053862-5 2004 The combination of pNGR-TNF or pRGD-TNF with doxorubicin or melphalan induced stronger effects than single agents. Doxorubicin 45-56 tumor necrosis factor Homo sapiens 36-39 11572767-0 2001 Augmented adriamycin sensitivity in cells transduced with an antisense tumor necrosis factor gene is mediated by caspase-3 downstream from reactive oxygen species. Doxorubicin 10-20 tumor necrosis factor Homo sapiens 71-92 12850194-6 2003 They have identified TNFalpha-mediated vasculotoxic effects on the tumour vasculature and have shown that addition of TNFalpha to the perfusate results in an increase of three to six times in uptake of melphalan or doxorubicin by tumours. Doxorubicin 215-226 tumor necrosis factor Homo sapiens 21-29 12850194-6 2003 They have identified TNFalpha-mediated vasculotoxic effects on the tumour vasculature and have shown that addition of TNFalpha to the perfusate results in an increase of three to six times in uptake of melphalan or doxorubicin by tumours. Doxorubicin 215-226 tumor necrosis factor Homo sapiens 118-126 12660450-0 2003 Synergism of Fas-mediated apoptosis and tumor necrosis factor on adriamycin cytotoxicity to transitional cell carcinoma. Doxorubicin 65-75 tumor necrosis factor Homo sapiens 40-61 12660450-4 2003 The synergism efficacy of Fas-mediated apoptosis and TNF-alpha on adriamycin cytotoxicity of TCC cells was analyzed. Doxorubicin 66-76 tumor necrosis factor Homo sapiens 53-62 12908082-0 2003 Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Doxorubicin 47-58 tumor necrosis factor Homo sapiens 13-22 12908082-7 2003 In H69 cells, TNF-alpha antigen levels were increased approximately fivefold in the conditioned medium of doxorubicin-treated cells, in parallel with an increase in mRNA levels. Doxorubicin 106-117 tumor necrosis factor Homo sapiens 14-23 13679856-5 2003 When HepG2 cells were transfected with ARK5 expression vector and subjected to several cell death stimuli, ARK5 was found to suppress cell death by glucose starvation, TRAIL, and TNF-alpha, but not by ultraviolet irradiation, camptothecin, or doxorubicin. Doxorubicin 243-254 tumor necrosis factor Homo sapiens 179-188 12660450-12 2003 CONCLUSIONS: Although the Fas antigen expression is common in TCC cells and apoptosis can be activated by the Fas/Fas ligand pathway activation, the synergistic cytotoxicity of adriamycin by the Fas/Fas ligand pathway is lower than that of TNF-alpha. Doxorubicin 177-187 tumor necrosis factor Homo sapiens 240-249 11572767-1 2001 While transduction of an antisense tumor necrosis factor (TNF) gene sequence can augment the cytotoxicity of adriamycin (ADM) in human cancer cells, the specific effect of introducing this sequence on the signal transduction pathway leading to cell death remains unclear. Doxorubicin 109-119 tumor necrosis factor Homo sapiens 35-56 11572767-1 2001 While transduction of an antisense tumor necrosis factor (TNF) gene sequence can augment the cytotoxicity of adriamycin (ADM) in human cancer cells, the specific effect of introducing this sequence on the signal transduction pathway leading to cell death remains unclear. Doxorubicin 109-119 tumor necrosis factor Homo sapiens 58-61 11389822-6 2001 High-dose TNF destructs tumor vasculature, and, most importantly, it enhances tumor-selective drug uptake (ie, melphalan and doxorubicin) by threefold to sixfold. Doxorubicin 125-136 tumor necrosis factor Homo sapiens 10-13 10880020-5 2000 The single doxorubicin and vincristine treatment of nude mice xenografted with pM3mdr-p-hTNF-transduced MCF-7 mammary tumors resulted in drug-induced and time-dependent elevation of intratumoral TNF-alpha expression at the mRNA and protein level. Doxorubicin 11-22 tumor necrosis factor Homo sapiens 88-92 11131649-6 2000 The review concludes with the possible application of low dose TNF-alpha, which can be given systemically, to enhance the anti-tumor potency of formulated drugs (such a liposomal doxorubicin) by increasing solid tumor targeting. Doxorubicin 179-190 tumor necrosis factor Homo sapiens 63-72 9713511-2 1998 Certain cytokines might be capable of bypassing this process and here we report on the in vitro effects of Tumor Necrosis Factor alpha, (TNF) on a MDR variant (FLC/DOX) of Friend leukemia. Doxorubicin 164-167 tumor necrosis factor Homo sapiens 107-134 9639400-0 1998 Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2. Doxorubicin 55-66 tumor necrosis factor Homo sapiens 24-51 9639400-12 1998 In conclusion, our data show that doxorubicin-resistant tumor cell lines with decreased topoisomerase IIalpha gene copies can become sensitive to TNF due to loss of c-erbB2 gene copies. Doxorubicin 34-45 tumor necrosis factor Homo sapiens 146-149 9935184-1 1999 We report here that stress stimuli such as gamma-irradiation or the anticancer drug doxorubicin activate expression of the death-inducing ligands (DILs) CD95-L, TNF-alpha and TRAIL. Doxorubicin 84-95 tumor necrosis factor Homo sapiens 161-170 9711910-4 1998 After TNF antisense cDNA was transfected into leukemic cells isolated from 5 patients, sensitivity of transfectants to DOX increased 1.4- to 2.5-fold. Doxorubicin 119-122 tumor necrosis factor Homo sapiens 6-9 9713511-2 1998 Certain cytokines might be capable of bypassing this process and here we report on the in vitro effects of Tumor Necrosis Factor alpha, (TNF) on a MDR variant (FLC/DOX) of Friend leukemia. Doxorubicin 164-167 tumor necrosis factor Homo sapiens 137-140 9713511-4 1998 Nevertheless, TNF exerts more cytotoxicity in FLC/DOX than in its parental, drug-sensitive, counterpart and this effect is related to the induction of apoptosis. Doxorubicin 50-53 tumor necrosis factor Homo sapiens 14-17 9713511-6 1998 We have tried to elucidate TNF signaling in FLC/DOX. Doxorubicin 48-51 tumor necrosis factor Homo sapiens 27-30 8899800-2 1996 In a previous report, we found that endogenous tumor necrosis factor (enTNF) exerts an intracellular protective effect against exogenous TNF- and Adriamycin (ADM)-induced cytotoxicity by scavenging oxygen free radicals (OFR) with induced manganous superoxide dismutase (MnSOD). Doxorubicin 146-156 tumor necrosis factor Homo sapiens 72-75 9116291-1 1997 We have previously reported that intracellular tumor necrosis factor (enTNF) is responsible for resistance, in established cell lines to doxorubicin (DOX), exogenous TNF, and heat stress by inducing manganous superoxide dismutase (MnSOD), thereby scavenging reactive oxygen free radicals. Doxorubicin 137-148 tumor necrosis factor Homo sapiens 72-75 9116291-1 1997 We have previously reported that intracellular tumor necrosis factor (enTNF) is responsible for resistance, in established cell lines to doxorubicin (DOX), exogenous TNF, and heat stress by inducing manganous superoxide dismutase (MnSOD), thereby scavenging reactive oxygen free radicals. Doxorubicin 150-153 tumor necrosis factor Homo sapiens 72-75 9116291-6 1997 KG-1 (human acute myelogenous leukemia) cells transfected with a nonsecretory-type TNF expression vector (pTNF delta pro) showed resistance to DOX. Doxorubicin 143-146 tumor necrosis factor Homo sapiens 83-86 8899800-7 1996 The sensitivity to TNF and ADM varied with the cell lines, and TNF sensitivity correlated well with Adriamycin sensitivity. Doxorubicin 100-110 tumor necrosis factor Homo sapiens 63-66 8899800-2 1996 In a previous report, we found that endogenous tumor necrosis factor (enTNF) exerts an intracellular protective effect against exogenous TNF- and Adriamycin (ADM)-induced cytotoxicity by scavenging oxygen free radicals (OFR) with induced manganous superoxide dismutase (MnSOD). Doxorubicin 158-161 tumor necrosis factor Homo sapiens 72-75 8899800-5 1996 In this study, we examined the relationship between ADM and exogenous TNF sensitivity and en-TNF expression and MnSOD activity in four pancreatic carcinoma lines. Doxorubicin 52-55 tumor necrosis factor Homo sapiens 70-73 8856983-3 1996 TNF or LT pretreatment, which can induce the synthesis of "protective" proteins such as mitochondrial manganese superoxide dismutase (MnSOD), protects animals from lethal doses of radiation or the chemotherapeutic drug doxorubicin. Doxorubicin 219-230 tumor necrosis factor Homo sapiens 0-3 8858979-4 1996 TNF endogenously secreted by human ovarian cancer cell lines is very efficient in potentiating the activity of DNA topoisomerase II inhibitors (doxorubicin, mitoxantrone, VP16). Doxorubicin 144-155 tumor necrosis factor Homo sapiens 0-3 7775261-0 1995 Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors. Doxorubicin 63-73 tumor necrosis factor Homo sapiens 12-33 7790119-7 1995 Release of transduced hTNF reduces P-glycoprotein expression and is associated with enhanced rhodamine-123 uptake and potentiation of cytotoxicity of the MDR-relevant drugs vincristine and doxorubicin. Doxorubicin 189-200 tumor necrosis factor Homo sapiens 22-26 9384669-0 1995 Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha. Doxorubicin 28-39 tumor necrosis factor Homo sapiens 104-131 9384669-8 1995 Though the molecular mechanism by which TNF-alpha was enhancing vindesine and doxorubicin cytotoxicity remained undefined in this study, the numbers of TNF-alpha binding sites on parental and on multidrug-resistant cells were similar, and P-glycoprotein expression was unmodulated during the entire 48 h incubation period. Doxorubicin 78-89 tumor necrosis factor Homo sapiens 40-49 7775261-3 1995 Pretreatment of HeLa cells, which produce an appreciable amount of enTNF and show apparent TNF resistance, with TNF followed by adriamycin (ADM) resulted in an additive effect, whereas pretreatment with ADM followed by TNF resulted in a synergistic effect. Doxorubicin 128-138 tumor necrosis factor Homo sapiens 69-72 7775261-3 1995 Pretreatment of HeLa cells, which produce an appreciable amount of enTNF and show apparent TNF resistance, with TNF followed by adriamycin (ADM) resulted in an additive effect, whereas pretreatment with ADM followed by TNF resulted in a synergistic effect. Doxorubicin 128-138 tumor necrosis factor Homo sapiens 91-94 7775261-3 1995 Pretreatment of HeLa cells, which produce an appreciable amount of enTNF and show apparent TNF resistance, with TNF followed by adriamycin (ADM) resulted in an additive effect, whereas pretreatment with ADM followed by TNF resulted in a synergistic effect. Doxorubicin 128-138 tumor necrosis factor Homo sapiens 91-94 7775261-3 1995 Pretreatment of HeLa cells, which produce an appreciable amount of enTNF and show apparent TNF resistance, with TNF followed by adriamycin (ADM) resulted in an additive effect, whereas pretreatment with ADM followed by TNF resulted in a synergistic effect. Doxorubicin 140-143 tumor necrosis factor Homo sapiens 69-72 7775261-3 1995 Pretreatment of HeLa cells, which produce an appreciable amount of enTNF and show apparent TNF resistance, with TNF followed by adriamycin (ADM) resulted in an additive effect, whereas pretreatment with ADM followed by TNF resulted in a synergistic effect. Doxorubicin 140-143 tumor necrosis factor Homo sapiens 91-94 7775261-3 1995 Pretreatment of HeLa cells, which produce an appreciable amount of enTNF and show apparent TNF resistance, with TNF followed by adriamycin (ADM) resulted in an additive effect, whereas pretreatment with ADM followed by TNF resulted in a synergistic effect. Doxorubicin 140-143 tumor necrosis factor Homo sapiens 91-94 7684321-4 1993 The present studies demonstrate that anti-Fas antibody in combination with diphtheria toxin (DTX), Adriamycin, or cis-platinum results in enhanced cytotoxicity and synergy and also overrides resistance to TNF, drugs, or toxins when tested against a battery of human tumor cell lines. Doxorubicin 99-109 tumor necrosis factor Homo sapiens 205-208 7914182-0 1994 Endogenous tumor necrosis factor functions as a resistant factor against adriamycin. Doxorubicin 73-83 tumor necrosis factor Homo sapiens 11-32 7914182-4 1994 In this study, we therefore examined the possibility that enTNF may act as a protective protein against adriamycin-induced cytotoxicity in a manner similar to that in which it protects against exogenous TNF and heat. Doxorubicin 104-114 tumor necrosis factor Homo sapiens 60-63 7914182-9 1994 These results indicate that enTNF exerts its intracellular protective effect against adriamycin-induced cytotoxicity by the same mechanism as that against exogenous TNF and heat, namely scavenging reactive oxygen with induced MnSOD. Doxorubicin 85-95 tumor necrosis factor Homo sapiens 30-33 7905787-7 1994 The implication of the manganese superoxide dismutase and endogenous TNF expression in the cross-resistance by MCF7AdrR cells to Adriamycin and TNF has also been investigated. Doxorubicin 129-139 tumor necrosis factor Homo sapiens 69-72 7905787-9 1994 This suggests a possible involvement of this enzyme in the Adriamycin-induced resistance to TNF. Doxorubicin 59-69 tumor necrosis factor Homo sapiens 92-95 7905787-12 1994 Furthermore, our data provide the first evidence that Adriamycin-induced resistance to TNF in MCF7AdrR cells may, in part, involve an overexpression of endogenous TNF and manganese superoxide dismutase genes. Doxorubicin 54-64 tumor necrosis factor Homo sapiens 87-90 7905787-12 1994 Furthermore, our data provide the first evidence that Adriamycin-induced resistance to TNF in MCF7AdrR cells may, in part, involve an overexpression of endogenous TNF and manganese superoxide dismutase genes. Doxorubicin 54-64 tumor necrosis factor Homo sapiens 163-166 8283917-0 1994 Tumor necrosis factor induces doxorubicin resistance to lung cancer cells in vitro. Doxorubicin 30-41 tumor necrosis factor Homo sapiens 0-21 8283917-5 1994 Pretreatment with tumor necrosis factor rendered cells resistant to subsequent 1-hour exposure to doxorubicin, a chemotherapeutic agent active against S phase cells. Doxorubicin 98-109 tumor necrosis factor Homo sapiens 18-39 8317554-7 1993 Enzyme induction with paraquat, adriamycin, or bleomycin was inhibitable by neutralizing antibody to interleukin-1 and tumor necrosis factor, suggesting that the inductions observed with these three drugs are due to the distal mediators, interleukin-1 or tumor necrosis factor released from the cells. Doxorubicin 32-42 tumor necrosis factor Homo sapiens 119-140 1651105-0 1991 Doxorubicin-induced cross-resistance to tumor necrosis factor (TNF) related to differential TNF processing. Doxorubicin 0-11 tumor necrosis factor Homo sapiens 40-61 8428693-4 1993 Enhanced cytotoxicity was seen with the combination of TNF-alpha and DOXO in each line regardless of their sensitivity or resistance patterns and, thus, demonstrates that drug resistance due to the expression of the MDR phenotype or its absence can be overcome by TNF-alpha and DOXO. Doxorubicin 69-73 tumor necrosis factor Homo sapiens 264-273 8428693-4 1993 Enhanced cytotoxicity was seen with the combination of TNF-alpha and DOXO in each line regardless of their sensitivity or resistance patterns and, thus, demonstrates that drug resistance due to the expression of the MDR phenotype or its absence can be overcome by TNF-alpha and DOXO. Doxorubicin 278-282 tumor necrosis factor Homo sapiens 264-273 1418895-3 1992 Interferon gamma significantly enhanced the cytotoxicity of tumor necrosis factor alpha with dactinomycin on all six cell lines investigated, while in four of six cell lines the cytotoxicity of tumor necrosis factor alpha with doxorubicin was significantly augmented by interferon gamma. Doxorubicin 227-238 tumor necrosis factor Homo sapiens 60-87 1418895-3 1992 Interferon gamma significantly enhanced the cytotoxicity of tumor necrosis factor alpha with dactinomycin on all six cell lines investigated, while in four of six cell lines the cytotoxicity of tumor necrosis factor alpha with doxorubicin was significantly augmented by interferon gamma. Doxorubicin 227-238 tumor necrosis factor Homo sapiens 194-221 1651105-0 1991 Doxorubicin-induced cross-resistance to tumor necrosis factor (TNF) related to differential TNF processing. Doxorubicin 0-11 tumor necrosis factor Homo sapiens 63-66 1651105-0 1991 Doxorubicin-induced cross-resistance to tumor necrosis factor (TNF) related to differential TNF processing. Doxorubicin 0-11 tumor necrosis factor Homo sapiens 92-95 1651105-8 1991 We conclude that cross-resistance to TNF in doxorubicin-resistant MCF-7 cells may be explained in part by altered TNF degradation. Doxorubicin 44-55 tumor necrosis factor Homo sapiens 37-40 1651105-8 1991 We conclude that cross-resistance to TNF in doxorubicin-resistant MCF-7 cells may be explained in part by altered TNF degradation. Doxorubicin 44-55 tumor necrosis factor Homo sapiens 114-117 2166714-6 1990 With 5 cell lines we also tested whether TNF affected the cytotoxicity of doxorubicin and etoposide, 2 topoisomerase II-targeted drugs which are widely used in the therapy of lung cancer. Doxorubicin 74-85 tumor necrosis factor Homo sapiens 41-44 2249897-1 1990 The effect of recombinant human tumor necrosis factor-alpha (rhTNF-alpha) on anti-tumor activity of adriamycin entrapped in small unilamellar liposomes (ADM-Lip) has been studied using BALB/c mice bearing subdermal Meth-A fibrosarcoma. Doxorubicin 100-110 tumor necrosis factor Homo sapiens 32-59 2227544-3 1990 We examined the cytotoxic effect of a combined modality using a variety of concentrations of recombinant tumor necrosis factor (rTNF) (a cytotoxic cytokine) with Adriamycin (ADR) and cisplatin (CDDP) on human ovarian carcinoma cell lines. Doxorubicin 162-172 tumor necrosis factor Homo sapiens 105-126 34932406-6 2022 Our data shows a significant (p<0.05) increase in glucose levels, apoptotic markers, monocyte infiltration at the site of apoptosis and triggered inflammatory immune response (TNF-alpha and IL-6), in DOX+STZ animals compared to control and experimental groups. Doxorubicin 200-203 tumor necrosis factor Homo sapiens 176-185 2362291-4 1990 Both the suramin-TNF-alpha and the doxorubicin-TNF-alpha combinations showed synergistic action against the LNCaP line. Doxorubicin 35-46 tumor necrosis factor Homo sapiens 47-56 2363856-0 1990 Augmentation of the effect of doxorubicin with low-dose tumor necrosis factor in experimental liver metastasis. Doxorubicin 30-41 tumor necrosis factor Homo sapiens 56-77 2363856-4 1990 Lower dosages of tumor necrosis factor, 10 micrograms, 5 micrograms, and 1 microgram, administered with 10 mg/kg of doxorubicin (Adriamycin) significantly enhanced the antitumor effect of doxorubicin without an acute mortality. Doxorubicin 116-127 tumor necrosis factor Homo sapiens 17-38 2363856-4 1990 Lower dosages of tumor necrosis factor, 10 micrograms, 5 micrograms, and 1 microgram, administered with 10 mg/kg of doxorubicin (Adriamycin) significantly enhanced the antitumor effect of doxorubicin without an acute mortality. Doxorubicin 129-139 tumor necrosis factor Homo sapiens 17-38 2363856-4 1990 Lower dosages of tumor necrosis factor, 10 micrograms, 5 micrograms, and 1 microgram, administered with 10 mg/kg of doxorubicin (Adriamycin) significantly enhanced the antitumor effect of doxorubicin without an acute mortality. Doxorubicin 188-199 tumor necrosis factor Homo sapiens 17-38 34656704-7 2022 Moreover, AML mitigated DOX-induced neuroinflammation and decreased hippocampal tumor necrosis factor-alpha level, nuclear factor kappa-B, and cyclooxygenase-2 expression. Doxorubicin 24-27 tumor necrosis factor Homo sapiens 80-107 34547383-12 2021 Meanwhile, DOX further increased the elevation of plasma IL-6, IL-1beta and TNF-alpha induced by DMM and obviously reduced the expression of chondrocyte differentiation-related markers, including collagen type II a1 (Col2A1), collagen type X alpha 1 (Col10A1), and aggrecan. Doxorubicin 11-14 tumor necrosis factor Homo sapiens 76-85 34120620-9 2021 DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-alpha and IL-1beta. Doxorubicin 0-3 tumor necrosis factor Homo sapiens 256-265